This is a routine insider purchase by a non-executive chair with no material impact on AZN's valuation or outlook. Monitor for any subsequent larger insider transactions or changes in institutional ownership for broader sentiment signals.
Price Chart
Executive Summary
AstraZeneca's Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares at £121.21 per share on 14 September 2026, a routine insider buy of approximately £303,000. This is a small, non-material open-market purchase by a non-executive director, representing a modest alignment signal but negligible relative to a $254B market cap. The filing is routine and carries no actionable trading signal.
Key Facts
- Non-Executive Chair Michel Demaré purchased 2,500 ordinary shares on 14 September 2026.
- Purchase price was £121.213296 per share, total value approximately £303,033.
- Transaction was an open-market purchase on the London Stock Exchange (LON).
- No other material financial or operational information was disclosed in this filing.
Financial Impact
Approximately £303,000 (GBP) open-market purchase by a non-executive director — immaterial relative to $254B market cap.
Risk Factors
- Insider purchase is too small to signal any material conviction or change in business outlook.
- No other financial or operational data in this filing to assess company performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (AZN) — Batch item 1 | 0001654954-26-008367 |
| Document: 0001654954-26-008367-index-headers.html | 0001654954-26-008367 |
| Document: 0001654954-26-008367-index.html | 0001654954-26-008367 |
| Document: 0001654954-26-008367.txt | 0001654954-26-008367 |
| 6-K Filing (AZN) — Batch item 5 | 0001654954-26-008367 |
| Document: 0001654954-26-008367-index-headers.html | 0001654954-26-008367 |
| Document: 0001654954-26-008367-index.html | 0001654954-26-008367 |
| Document: 0001654954-26-008367.txt | 0001654954-26-008367 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.52 (−3.29%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.52 (+4.43%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.52 (−2.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.52 (−3.66%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.52 (−3.66%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.52 (+3.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access